Q2 2023 Earnings Forecast for Sarepta Therapeutics, Inc. Issued By Zacks Research (NASDAQ:SRPT)

Posted by on Jun 26th, 2023

Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Rating) – Equities researchers at Zacks Research reduced their Q2 2023 earnings per share estimates for shares of Sarepta Therapeutics in a note issued to investors on Wednesday, June 21st. Zacks Research analyst S. Ganoria now expects that the biotechnology company will post earnings of ($2.92) per share for the quarter, down from their previous forecast of ($2.88). The consensus estimate for Sarepta Therapeutics’ current full-year earnings is ($10.90) per share. Zacks Research also issued estimates for Sarepta Therapeutics’ Q3 2023 earnings at ($2.65) EPS, Q4 2023 earnings at ($1.63) EPS, FY2023 earnings at ($13.06) EPS, Q1 2024 earnings at ($1.67) EPS, Q2 2024 earnings at ($1.47) EPS, Q3 2024 earnings at ($0.97) EPS, Q4 2024 earnings at $0.01 EPS, FY2024 earnings at ($4.11) EPS and FY2025 earnings at $3.59 EPS.

Several other equities research analysts have also recently commented on SRPT. Needham & Company LLC cut their price target on Sarepta Therapeutics from $200.00 to $160.00 and set a “buy” rating for the company in a report on Friday, March 17th. Credit Suisse Group lowered their price objective on shares of Sarepta Therapeutics from $151.00 to $141.00 in a research note on Wednesday, May 24th. Oppenheimer cut their price target on Sarepta Therapeutics from $180.00 to $150.00 and set an “outperform” rating on the stock in a report on Thursday, March 9th. UBS Group lifted their price target on shares of Sarepta Therapeutics from $160.00 to $173.00 in a research note on Monday, May 15th. Finally, The Goldman Sachs Group raised their price target on Sarepta Therapeutics from $171.00 to $190.00 and gave the company a “buy” rating in a research note on Wednesday, March 1st. Two research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. According to MarketBeat, Sarepta Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $169.81.

Sarepta Therapeutics Stock Down 7.9 %

SRPT opened at $114.09 on Monday. The company has a quick ratio of 4.26, a current ratio of 4.63 and a debt-to-equity ratio of 1.73. Sarepta Therapeutics has a twelve month low of $70.32 and a twelve month high of $159.89. The company has a market cap of $10.63 billion, a PE ratio of -8.99 and a beta of 1.01. The company has a 50-day moving average price of $129.38 and a 200 day moving average price of $129.55.

Sarepta Therapeutics (NASDAQ:SRPT – Get Rating) last issued its quarterly earnings results on Tuesday, May 2nd. The biotechnology company reported ($0.97) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.46) by $0.49. Sarepta Therapeutics had a negative net margin of 114.30% and a negative return on equity of 128.64%. The business had revenue of $253.50 million for the quarter, compared to analyst estimates of $241.47 million. During the same quarter in the prior year, the business posted ($1.20) EPS. Sarepta Therapeutics’s revenue for the quarter was up 20.2% compared to the same quarter last year.

Hedge Funds Weigh In On Sarepta Therapeutics

Institutional investors have recently made changes to their positions in the business. EFG Asset Management Americas Corp. raised its holdings in Sarepta Therapeutics by 4.6% during the first quarter. EFG Asset Management Americas Corp. now owns 1,738 shares of the biotechnology company’s stock worth $240,000 after acquiring an additional 77 shares in the last quarter. FourThought Financial LLC grew its stake in shares of Sarepta Therapeutics by 43.5% in the third quarter. FourThought Financial LLC now owns 297 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 90 shares in the last quarter. Xponance Inc. increased its holdings in Sarepta Therapeutics by 0.8% in the 1st quarter. Xponance Inc. now owns 11,487 shares of the biotechnology company’s stock valued at $1,583,000 after buying an additional 93 shares during the period. AQR Capital Management LLC increased its position in Sarepta Therapeutics by 3.5% during the 4th quarter. AQR Capital Management LLC now owns 2,826 shares of the biotechnology company’s stock worth $366,000 after purchasing an additional 95 shares in the last quarter. Finally, Exchange Traded Concepts LLC grew its holdings in Sarepta Therapeutics by 16.5% during the 4th quarter. Exchange Traded Concepts LLC now owns 685 shares of the biotechnology company’s stock worth $89,000 after acquiring an additional 97 shares during the last quarter. 85.59% of the stock is currently owned by institutional investors.

Sarepta Therapeutics Company Profile

(Get Rating)

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; and AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene.

Read More

Earnings History and Estimates for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.